| pubmed-article:17276055 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C0226896 | lld:lifeskim |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C0205531 | lld:lifeskim |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C1527415 | lld:lifeskim |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C0596087 | lld:lifeskim |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C0205177 | lld:lifeskim |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C1334306 | lld:lifeskim |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C1336602 | lld:lifeskim |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C1705001 | lld:lifeskim |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C0034284 | lld:lifeskim |
| pubmed-article:17276055 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:17276055 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:17276055 | pubmed:dateCreated | 2007-2-23 | lld:pubmed |
| pubmed-article:17276055 | pubmed:abstractText | During our effort to develop dual VEGFR2 and Tie-2 inhibitors as anti-angiogenic agents for cancer therapy, we discovered 4-amino-5-(4-((2-fluoro-5-(trifluoromethyl)phenyl)- aminocarbonylamino)phenyl)furo[2,3-d]pyrimidine (8a) possessing strong inhibitory activity at both the enzyme and cellular level against VEGFR2 and Tie-2. Compound 8a demonstrated high pharmacokinetic exposure through oral administration, and showed marked tumor growth inhibition and anti-angiogenic activity in mouse HT-29 xenograft model via once-daily oral administration. | lld:pubmed |
| pubmed-article:17276055 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17276055 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17276055 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17276055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17276055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17276055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17276055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17276055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17276055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17276055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17276055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17276055 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17276055 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:17276055 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:SatoHideyukiH | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:NakanoMasatoM | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:MaedaYutakaY | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:NolteRobert... | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:OkamotoYujiY | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:TangJunJ | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:HasslerDaniel... | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:PatrickDenis... | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:WangLipingL | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:MiyazakiYasus... | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:TruesdaleAnne... | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:NarteyEldridg... | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:HoMaureen LML | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:SugaiMasakiM | lld:pubmed |
| pubmed-article:17276055 | pubmed:author | pubmed-author:OzawaKazunori... | lld:pubmed |
| pubmed-article:17276055 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17276055 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:17276055 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:17276055 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17276055 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17276055 | pubmed:pagination | 1773-8 | lld:pubmed |
| pubmed-article:17276055 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:meshHeading | pubmed-meshheading:17276055... | lld:pubmed |
| pubmed-article:17276055 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17276055 | pubmed:articleTitle | Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2. | lld:pubmed |
| pubmed-article:17276055 | pubmed:affiliation | GlaxoSmithKline, Tsukuba Research Laboratories, 43, Wadai, Tsukuba 300-4247, Ibaraki, Japan. yasushi.miyazaki@gsk.com | lld:pubmed |
| pubmed-article:17276055 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17276055 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17276055 | lld:pubmed |
